In clinical practice, it is interesting to note that the antitumor efficacy of administered IFNα2 is associated with the development of autoimmune manifestations [13], whereas IFNβ is routinely used for treatment of multiple sclerosis, which is considered to be an inflammatory autoimmune disease [1]. Here, IFNA2 is linked to multiple sclerosis.